IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment

University of Roma La Sapienza589 enrolled

Overview

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

Study Type

OBSERVATIONAL

Enrollment

589

Conditions

Cognitive Impairment Insulin-like Growth Factor 1

Interventions

IGF-1 serum valuePROCEDURE

Evaluation of IGF-1 serum value at baseline, 24 and 48 months

Eligibility

Sex: ALLMin age: 65 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of cognitive impairment (MMSE \< 24) * Age \> 65 ys Exclusion Criteria: * Diagnosis of pancreatic disorders * Diagnosis of acromegaly * Diagnosis of GH-related disorders * Recent bone fractures or immobility before the enrollment (3 months) * Cancer

Locations (2)

IRCCS Galeazzi

Milan, Italy, Italy

Sapienza University of Rome

Rome, Italy, Italy

Outcomes

Primary Outcomes

IGF-1 reduction in patients with sarcopenia

IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment

Time frame: baseline, 24 months, 48 months

Secondary Outcomes

IGF-1 reduction and mortality in patients with cognitive impairment

IGF-1 could be an independent risk factor for mortality in patients with cognitive impairment

Time frame: baseline, 24 months, 48 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.